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We analyzed the effectiveness of personal protective 
equipment and oseltamivir use during the 2003 avian in-
ﬂ  uenza A (H7N7) epidemic in the Netherlands by linking 
databases containing information about farm visits, human 
infections, and use of oseltamivir and personal protective 
equipment. Using a stringent case deﬁ   nition, based on 
self-reported conjunctivitis combined with a positive he-
magglutination-inhibition assay, we found that prophylactic 
treatment with oseltamivir signiﬁ  cantly reduced the risk for 
infection per farm visit from 0.145 (95% conﬁ  dence inter-
val [CI] 0.078–0.233) to 0.031 (95% CI 0.008–0.073). The 
protective effect was ≈79% (95% CI 40%–97%). These 
results are comparable with the reported effect of prophy-
lactic treatment with oseltamivir on human seasonal inﬂ  u-
enza. No signiﬁ  cant protective effect was found for use of 
respirators or safety glasses, possibly because of limita-
tions of the data.
A
vian inﬂ  uenza A viruses are considered a threat to 
public health because they may result in new human 
inﬂ  uenza A strains. Thus, knowledge about preventing hu-
man infections with avian inﬂ  uenza viruses is essential. In 
2003, a devastating epidemic caused by an avian inﬂ  uenza 
virus of subtype H7N7 occurred among the poultry sector 
of the Netherlands (1). During this epidemic, an unexpect-
edly high number of persons reported illness that appeared 
to be associated with subtype H7N7 infection after they 
were exposed to infected poultry (2); 1 veterinarian died 
of acute respiratory distress syndrome (3). Previous reports 
have documented transmission between poultry, between 
humans, and from poultry to humans (1,4–8). In this report, 
we extend earlier work by analyzing the effect of personal 
protective measures on poultry-to-human transmission. 
Speciﬁ  cally, we investigated the effects of use of respira-
tors and safety glasses and the prophylactic use of oseltami-
vir on the risk for infection during depopulation of infected 
farms. Our quantitative estimates of the effect of personal 
protective measures can guide efforts to prevent human in-
fections with avian inﬂ  uenza.
Materials and Methods
Data
Immediately after the epidemic, the National Insti-
tute of Public Health and the Environment of the Nether-
lands sent a questionnaire to 1,747 persons, of whom 872 
(49.9%) responded. Response was lowest among persons 
who actively handled the culling of poultry (9). Of the 872 
persons who responded, 450 could be linked to a farm-
visits database kept during the epidemic that contained 
information about who had visited which farm on which 
date for what reason. Of these 450 persons, 194 had been 
actively involved in hands-on culling during the depopu-
lation; activities included catching live poultry and pick-
ing up dead poultry. Because this group had the highest 
exposure (4), it was used to analyze the effect of personal 
preventive measures.
The questionnaire asked for information about symp-
toms of infection of the eyes, from which a self-reported 
conjunctivitis result was derived as an outcome measure 
for subtype H7N7 infection. The presence of >2 of the fol-
lowing eye symptoms was classiﬁ  ed as conjunctivitis: red-
ness, tearing, itchiness, pain, burning, purulence, or sensi-
tivity to light. Blood samples were collected from survey 
respondents 3 weeks after possible exposure and tested by 
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a hemagglutination-inhibition (HI) assay for antibodies by 
using a modiﬁ  ed cutoff based on validation studies of per-
sons known to be infected and of nonexposed controls (10). 
The serologic result was available in addition to the self-
reported conjunctivitis information.
We used a case deﬁ  nition that combined both out-
comes, i.e., a person needed to self-report conjunctivitis 
and have a positive HI assay result. For sensitivity analysis, 
both the conjunctivitis and the serologic result were used in 
separate case deﬁ  nitions.
The survey also contained information about prophy-
laxis with a neuraminidase inhibitor (oseltamivir [Tamiﬂ  u; 
Roche, Basel, Switzerland]) and the use of personal protec-
tive equipment (PPE [safety glasses and respirator]). Be-
ginning on March 14, prophylaxis with oseltamivir (75 mg 
daily) was prescribed to persons in contact with potentially 
infected poultry (2 weeks after the ﬁ  rst infection was di-
agnosed and 10 days after culling began). Continuation of 
oseltamivir treatment was recommended until 2 days after 
possible exposure. The subtype H7N7 strain that circulat-
ed was susceptible to oseltamivir (2). To determine osel-
tamivir use, persons were asked the following questions: 
1) Were you prescribed oseltamivir by a medical doctor? 
(yes/no). 2) If oseltamivir was prescribed, when was it pre-
scribed and when did you stop using it? 3) How often did 
you fail to take a capsule? Persons who were not prescribed 
oseltamivir were classiﬁ  ed as “did not use.” On the basis 
of the period of use stated in the survey, persons who were 
prescribed oseltamivir were classiﬁ  ed per visit as “used” 
or “did not use.” Within the used category, persons who 
missed <3 capsules were classiﬁ  ed as consistent users; if 
more capsules were missed, they were classiﬁ  ed as incon-
sistent users. 
PPE (respirator and safety glasses) were provided dur-
ing the entire epidemic to persons involved in the depopu-
lation. The Dutch Food and Consumer Product Safety Au-
thority provided the PPE and supervised its use. For each 
visit, workers received new PPE. They were instructed how 
to use the PPE but received no extensive training. For both 
respirators and safety glasses, workers were asked the fol-
lowing questions: 1) Did you use respirators/safety glass-
es (yes/no)? 2) How often did you use respirators/safety 
glasses (always, almost always, sometimes, almost never, 
never)? 3) How often did you not use respirators/safety 
glasses? From responses to these questions, we classiﬁ  ed 
persons into 3 categories: used, sometimes used, and did 
not use. Persons who had either always or almost always 
used respirators or safety glasses and who stated that they 
had not missed using them more than twice were placed in 
the “used” category. Persons who had not used them were 
classiﬁ  ed as did not use, and all remaining persons with an-
swers were classiﬁ  ed as sometimes used. For safety glasses 
and respirators, information was available only about their 
use during the whole epidemic and not per visit. We there-
fore assumed that a person’s use of a respirator and safety 
glasses did not change during the epidemic. The respirators 
provided were type FFP2 (US equivalent N95, Figure 1), 
which protected both nose and mouth and were all the same 
size. Safety glasses covered only the front of the eyes and 
were open above, below, and on both sides of the eyes (Fig-
ure 1). They were effective against splashes but not against 
dust. No information was available about the overall health 
of the workers.
Statistical Analysis
The probability of becoming infected during a visit was 
calculated from the number of visits each person had made 
and whether each person was infected (according to the case 
deﬁ  nitions). The analysis comprised only visits to farms with 
infected poultry. During each visit, a person could either es-
cape infection or become infected. The probability of each 
sequence of events could be added, from which the prob-
ability of infection per visit could be estimated by maximum 
likelihood (online Technical Appendix, www.cdc.gov/eid/
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Figure 1. Poultry worker wearing respirator and safety glasses, the 
Netherlands, 2003.RESEARCH
content/16/10/1562-Techapp.pdf). The dependent variable 
in this analysis was the case deﬁ  nition, i.e., whether a person 
was infected. The probability of infection was calculated ac-
cording to the categorical level of personal protection used, 
e.g., use of oseltamivir or not, as independent variables. We 
calculated conﬁ  dence intervals (CIs) using proﬁ  le likelihood 
methods (11). Statistical testing was performed by using 
likelihood ratio tests (11).
For oseltamivir, risk for infection was calculated per 
group and then aggregated over the groups of persons who 
had and had not used oseltamivir (Tables 1, 2). Use of res-
pirators, safety glasses, and oseltamivir were classiﬁ  ed into 
the earlier described groups. We then calculated the risk 
for infection for each combination of groups, e.g., always 
used respirators/sometimes used safety glasses (Tables 
3, 4). Although onset date of infection was unknown, the 
likelihood function took into account that a person could 
become infected only once and that infection could occur 
at any farm visit.
Results
The 194 persons analyzed together had made 458 ac-
tive culling visits. A conjunctivitis result was available for 
193 persons (36 positive), a serologic result for 131 persons 
(81 positive), and a combined conjunctivitis/serology result 
for 130 persons (19 positive). Mean age of the study popu-
lation was 40 years (range 18–64 years). Most (110) per-
sons were veterinarians. Ninety percent of the study popu-
lation was male. Persons made an average of 2.4 (range 
1–9) active culling visits.
Oseltamivir
Oseltamivir had been prescribed for 159 persons; 35 
stated that oseltamivir had not been prescribed. Forty-ﬁ  ve 
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Table 1. Number of infections and use of oseltamivir prophylaxis during avian influenza A (H7N7) epidemic, on the basis of combined
conjunctivitis and serology-based case definition, the Netherlands, 2003* 
Oseltamivir use
No. persons  No. visits 
Infected Total By infected persons  Total† 
Not prescribed  4 16 6 26
Prescribed but not used during visit  9 34 17 64
Prescribed and used consistently  4 41 6 85
Prescribed and used inconsistently  2 18 7 39
Prescribed and consistency of use unknown  2 7 2 18
Prescribed but period of use unknown  2 29 5 64
*Data resulted from a survey conducted among poultry workers after the epidemic. 
†Because visits were classified into groups, persons may be in 2 categories (prescribed/not used and prescribed/used). 
Table 2. Risk for infection with avian influenza A (H7N7) with different levels of oseltamivir use, on the basis of combined conjunctivitis
and serology-based case definition, the Netherlands, 2003* 
Oseltamivir use  Risk† (95% CI) 
Not used  0.145 (0.078–0.233) 
 Not  prescribed  0.161 (0.052–0.336) 
  Prescribed but not used during visit  0.138 (0.061–0.246) 
Used 0.031 (0.008–0.073) 
  Prescribed and used consistently  0.015 (0.0008–0.0630) 
  Prescribed and used inconsistently  0.049 (0.004–0.157) 
  Prescribed and consistency of use unknown  0.068 (0.004–0.258) 
Unknown  0.019 (0.001–0.080) 
  Prescribed but period of use unknown  0.020 (0.001–0.080) 
*CI, confidence interval. 
†Probability of infection per visit.  
Table 3. Number of infections and use of respirator and safety glasses during avian influenza A (H7N7) epidemic, on the basis of
combined conjunctivitis and serology-based case definition, the Netherlands, 2003* 
Respirator used  Safety glasses used 
No. persons  No. visits 
Infected Total By infected persons  Total
Always Always  1 19 3 44
Sometimes 5 19 13 53
Not used 4 27 8 45
Sometimes Always – – – –
Sometimes 3 17 11 58
Not used 2 22 3 45
Not used  Not used  3 4 4 8
Unknown Unknown  1  22  1  43 
*Data resulted from a survey conducted among poultry workers after the epidemic.  –, no data in this group. PPE and Oseltamivir Use
persons for whom oseltamivir had been prescribed did 
not use it during some of their visits. For the group of 130 
(combined case deﬁ  nition), oseltamivir was prescribed for 
114 and not prescribed for 16; for 34 persons, oseltamivir 
was prescribed but not used.
The estimated risk for infection per visit without use 
of oseltamivir was 0.145 (95% CI 0.078–0.233). This risk 
dropped signiﬁ  cantly to 0.031 (95% CI 0.008–0.073; p = 
0.005) per visit when oseltamivir was used (Table 2; Figure 
2). When calculated over the infection probabilities, osel-
tamivir use had a protective effect of 79% (95% CI 40%–
97%; relative risk [RR] 0.21, 95% CI 0.03–0.60). The risk 
for infection seemed to increase when oseltamivir was used 
inconsistently, but this risk did not reach signiﬁ  cance.
Results with case deﬁ  nitions that used either the se-
rologic results or self-reported conjunctivitis differed 
slightly. With the serologic result, the estimated risk for 
infection without oseltamivir use was 0.513 (95% CI 
0.370–0.656). This risk dropped to 0.274 (95% CI 0.157–
0.418; p = 0.01) with oseltamivir use (Tables 5, 6), which 
resulted in a protective effect of 46% (95% CI 19%–68%; 
RR 0.54, 95% CI 0.32–0.81). With self-reported conjunc-
tivitis used as case deﬁ  nition, the estimated risk for infec-
tion without oseltamivir use was 0.115 (95% CI 0.064–
0.180). This risk dropped to 0.073 (95% CI 0.032–0.135; 
p = 0.08) with oseltamivir use (Tables 5, 7), which re-
sulted in a protective effect of 53% (95% CI 2%–82%; RR 
0.47, 95% CI 0.18–0.98).
We could not analyze interactions between use of 
oseltamivir and PPE because the resulting groups would 
have had too few visits. In the group that always used res-
pirators and protective glasses and the group that some-
times used respirators and protective glasses, oseltamivir 
use was relatively equal (63%–74%). In the group that 
sometimes used respirators and did not use safety glasses, 
oseltamivir was used in 38% of the visits. In the group 
that did not use safety glasses or respirators, oseltamivir 
was used in 25% of the visits. These ﬁ  ndings indicate no 
strong correlation.
Respirators and Safety Glasses
Persons generally were more inclined to use respira-
tors than safety glasses (Tables 3, 8). Persons who always 
used safety glasses also used a respirator. Only a small 
number of persons stated they had used no respirator and 
no safety glasses.
We gauged the effect of using safety glasses by com-
paring the risk for infection in persons with different safety 
glasses use within the group who always used respirators 
(Table 4). Within this group, risk for infection decreased with 
use of safety glasses; however, this trend was not signiﬁ  cant. 
We gauged the effect of respirator use by comparing the risk 
for infection in persons with equal levels of safety glasses 
use but different respirator use (Table 4). Risk for infection 
was lower in persons who sometimes used a respirator than 
in persons who always used a respirator (within the groups 
that sometimes used or did not use safety glasses). Risk was 
higher for persons who had not used respirators than for 
those who had sometimes or always used them (within the 
group that had not used safety glasses). However, the group 
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Table 4. Risk for infection with avian influenza A (H7N7) with different levels of respirator and safety glasses use, on the basis of 
combined conjunctivitis and serology-based case definition, the Netherlands, 2003* 
Respirator used  Safety glasses used  Risk† (95% CI) 
Always Always  0.023 (0.001–0.099) 
Sometimes 0.079 (0.018–0.188) 
Not used  0.093 (0.029–0.204) 
Sometimes Always –
Sometimes 0.056 (0.014–0.14) 
Not used  0.045 (0.007–0.133) 
Not used  Not used  0.408 (0.119–0.755) 
Unknown Unknown  0.023 (0.001–0.099) 
*CI, confidence interval; –, no data in this group. 
†Probability of infection per visit.  
Figure 2. Point estimates and 95% conﬁ  dence intervals of the risk 
for infection per visit in relation to oseltamivir use for the combined 
serology/conjunctivitis case deﬁ  nition, the Netherlands, 2003.RESEARCH
that had used neither respirators nor safety glasses was small. 
In both comparisons, the protective effect of respirators was 
not statistically signiﬁ  cant. In the sensitivity analysis, results 
for which conjunctivitis and the serologic result were used 
as case deﬁ  nitions were similar to results with the combined 
case deﬁ  nition (Table 9).
Discussion
Quantiﬁ  cations of the effect of prophylactic use of os-
eltamivir on the risk for infection with avian inﬂ  uenza A 
(H7N7) virus can be used to guide efforts to reduce hu-
man infections with avian inﬂ  uenza. The risk for infection 
per visit was remarkably high among persons who did not 
use prophylactic oseltamivir (0.145, 95% CI 0.078–0.233). 
Although signiﬁ  cantly lower, the risk for infection per visit 
for persons who did use oseltamivir prophylactically was 
still considerable (0.031, 95% CI 0.008–0.073).
Given the lack of research on the prophylactic effect of 
oseltamivir use on avian inﬂ  uenza in humans, we compared 
our result with studies on human seasonal inﬂ  uenza. Our es-
timated protective effect of oseltamivir use (79%) compares 
with that reported for laboratory-conﬁ  rmed  symptomatic 
human seasonal inﬂ  uenza, which ranges from 68% to 90% 
(12–17). The protective effect estimated with the case deﬁ  ni-
tion based on the serologic result only (46%) is close to the 
range of 49%–68% found with laboratory-conﬁ  rmed human 
inﬂ  uenza (12–14). This ﬁ  nding suggests that the speciﬁ  city 
of the serologic outcome measure is high, even though in our 
study it has a relatively low cutoff (10). The standard for use 
of HI assays in serologic studies is a cutoff of 40. This cutoff 
was lowered on the basis of evidence from an epidemiologic 
study in which no serologic responses were found in any of 
the 89 known infected persons by using the standard criteria, 
but a high proportion had low-level antibody reactivity with 
high speciﬁ  city, which has triggered some debate about the 
validity of this serologic approach. However, ﬁ  nding a sig-
niﬁ  cantly lower risk for persons that used oseltamivir and 
had antibody reactivity cannot be explained by nonspeciﬁ  c 
reactivity. Therefore, we conclude that, for some reason, 
subtype H7N7 infections do not provoke a strong immune 
response, possibly related to the ocular tropism. Since then, 
similar ﬁ  ndings have been reported (18,19). Finally, the pro-
tective effect when conjunctivitis is used as case deﬁ  nition 
was 53% in our study, compared with 29% for human inﬂ  u-
enza based on inﬂ  uenza-like illness (14), which suggests a 
reasonable speciﬁ  city of conjunctivitis as indicator for sub-
type H7N7 infection.
Considering the effect of oseltamivir in reducing the 
risk for infection, prophylactic treatment of all persons in-
volved in depopulating farms may seem wise. However, os-
eltamivir is also the fallback drug used for treating patients 
with severe inﬂ  uenza, and resistance against oseltamivir 
has increased in seasonal inﬂ  uenza viruses (20). A deci-
sion regarding prophylactic use of oseltamivir in a future 
epidemic would need to account for the risk for infection, 
risk for resistance, and severity of the infection.
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Table 5. Comparison of conjunctivitis and serologic result case definitions for number of infections and prophylactic oseltamivir use 
during avian influenza A (H7N7) epidemic, the Netherlands, 2003*  
Oseltamivir use 
Conjunctivitis Serologic result
Persons† Visits‡ Persons Visits
Not prescribed 6/35 9/63 12/16 22/26
Prescribed but not used during visit 12/45 25/80 26/34 48/64
Prescribed and used consistently 7/54 9/113 24/41 54/85
Prescribed and used inconsistently 5/26 13/65 11/18 24/39
Prescribed and consistency of use unknown 4/9 8/23 4/7 11/18
Prescribed but period of use unknown 9/47 15/109 17/30 40/68
*Data resulted from a survey conducted among poultry workers after the epidemic. 
†No. persons infected/total no. persons. 
‡No. visits by infected persons/total no. visits. Because visits were classified into groups, persons may be in 2 categories (prescribed not used and 
prescribed used). 
Table 6. Risk for infection with avian influenza A (H7N7) with different levels of oseltamivir use, on the basis of serologic result as case 
definition, the Netherlands, 2003* 
Oseltamivir use Risk† (95% CI)
Not used 0.513 (0.370–0.656) 
 Not  prescribed 0.653 (0.398–0.870)
  Prescribed but not used during visit 0.446 (0.277–0.623) 
Used 0.275 (0.182–0.381) 
  Prescribed and used consistently 0.294 (0.178–0.432)
  Prescribed and used inconsistently 0.281 (0.117–0.493) 
  Prescribed and consistency of use unknown 0.181 (0.016–0.502) 
Unknown 0.274 (0.157–0.418) 
  Prescribed but period of use unknown 0.274 (0.157–0.419)
*CI, confidence interval. 
†Probability of infection per visit. PPE and Oseltamivir Use
Although our results provided clear evidence that pro-
phylactic use of oseltamivir is effective in reducing risk for 
infection, the results were less clear with regard to PPE. In 
fact, although use of safety glasses appeared to reduce the 
risk for subtype H7N7 infection, this effect was not sig-
niﬁ   cant. Considering that the main symptom of subtype 
H7N7 is conjunctivitis, safety glasses may protect the eyes 
to some extent against inﬂ  uenza infection. For respirators, 
we also did not ﬁ  nd a clear protective effect. Persons who 
always wore respirators may have done work that exposed 
them more. For both respirators and safety glasses, people 
received a limited amount of training that perhaps led to in-
effective use of PPE and unsafe removal of contaminated 
PPE. Respirators were available in only 1 size and thus may 
not have ﬁ  t well. The safety glasses were effective against 
splashes but were open on all sides and were not effective 
against dust. Possibly the PPE used were not appropriate for 
the high-exposure work. The number of available visits per 
group was low, data were also of limited temporal resolution 
(because PPE use per visit was not available), and potential 
for a recall bias also existed. Because of these limitations, 
we cannot conclusively determine from this study that respi-
rators and safety glasses do not provide a protective effect. 
Findings of an experimental situation (21,22) indicated that 
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Table 8. Comparison of conjunctivitis and serologic result case definitions for number of infections and use of respirators and safety 
glasses during avian influenza A (H7N7) epidemic, the Netherlands, 2003* 
Use of respirator  Use of safety glasses 
Conjunctivitis Serology
Persons† Visits‡ Persons Visits
Always Always 3/28 5/60 11/19 30/44
Sometimes 7/25 16/76 12/19 38/53
Not used 7/38 14/65 19/27 32/45
Sometimes Always – – – –
Sometimes 4/25 13/84 10/18 40/62
Not used 5/28 12/62 10/22 19/45
Not used Not used 4/14 6/34 4/4 8/8
Unknown Unknown 6/35 13/72 15/22 32/43
*Data resulted from a survey conducted among poultry workers after the epidemic. Totals of respirator and safety glasses use can be derived by adding 
up the separate groups. –, no data in this group. 
†No. infected persons/total no. persons. 
‡No. visits by infected persons/total no. visits. 
Table 7. Risk for infection with avian influenza A (H7N7) with different levels of oseltamivir use, on the basis of conjunctivitis as case 
definition, the Netherlands, 2003* 
Oseltamivir use Risk† (95% CI)
Not used 0.115 (0.064–0.180) 
 Not  prescribed 0.098 (0.040–0.189)
  Prescribed but not used during visit 0.127 (0.055–0.227)
Used 0.054 (0.026–0.097) 
  Prescribed and used consistently 0.041 (0.012–0.091)
  Prescribed and used inconsistently 0.052 (0.010–0.135)
  Prescribed and consistency of use unknown 0.149 (0.029–0.360)
Unknown 0.073 (0.032–0.135) 
  Prescribed but period of use unknown 0.073 (0.032–0.135)
*CI, confidence interval. 
†Probability of infection per visit.  
Table 9. Comparison of conjunctivitis and serologic result case definitions for risk for infection with avian influenza A (H7N7) with 
different level of respirator and safety glass use, the Netherlands, 2003* 
Use of respirator  Use of safety glasses 
Risk† with conjunctivitis used as case 
definition (95% CI) 
Risk† with serology used as case 
definition (95% CI) 
Always  Always  0.051 (0.012–0.127)  0.338 (0.181–0.534) 
Sometimes 0.063 (0.017–0.144)  0.274 (0.125–0.471) 
Not used  0.115 (0.050–0.210)  0.494 (0.320–0.672) 
Sometimes Always – –
Sometimes 0.050 (0.015–0.114)  0.222 (0.108–0.380) 
Not used  0.082 (0.027–0.173)  0.233 (0.118–0.383) 
Not used  Not used  0.121 (0.039–0.261)  1 (0.463–1) 
Unknown  Unknown  0.088 (0.035–0.171)  0.48 (0.296–0.676) 
*CI, confidence interval; –, no data because no persons in this group sometimes used a respirator and always used safety glasses.
†Probability of infection per visit. RESEARCH
respirators are likely to modify exposure and thus risk for 
infection. In Norfolk, United Kingdom, in 2006, incomplete 
use of PPE (safety glasses and respirator) was associated 
with conjunctivitis and inﬂ  uenza-like illness in an outbreak 
of avian inﬂ  uenza A (H7N3) (23).
In our study, prophylactic use of oseltamivir greatly 
reduced risk for infection with avian inﬂ  uenza A (H7N7). 
However, even with oseltamivir use, risk for infection re-
mains considerable. Oseltamivir use should be part of an 
integrated approach to reduce human exposure, together 
with the use and appropriate training of PPE.
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